Sarepta Therapeutics Company Profile (NASDAQ:SRPT)

About Sarepta Therapeutics

Sarepta Therapeutics logoSarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company's lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRPT
  • CUSIP:
Key Metrics:
  • Previous Close: $25.76
  • 50 Day Moving Average: $24.42
  • 200 Day Moving Average: $19.26
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.67
  • P/E Growth: 24.95
  • Market Cap: $1.28B
  • Outstanding Shares: 47,899,000
  • Beta: 1.72
Additional Links:
Companies Related to Sarepta Therapeutics:

Analyst Ratings

Consensus Ratings for Sarepta Therapeutics (NASDAQ:SRPT) (?)
Ratings Breakdown: 5 Sell Ratings, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.11)
Consensus Price Target: $24.50 (8.51% downside)

Analysts' Ratings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateFirmActionRatingPrice TargetDetails
8/15/2016Cowen and CompanyReiterated RatingMarket PerformView Rating Details
8/11/2016Janney Montgomery ScottReiterated RatingNeutral$30.00View Rating Details
8/4/2016Leerink SwannReiterated RatingUnderperform$5.00View Rating Details
7/26/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$60.00View Rating Details
7/24/2016JMP SecuritiesReiterated RatingUnderperform$10.00View Rating Details
7/22/2016Needham & Company LLCBoost Price TargetBuy$20.00 -> $26.00View Rating Details
7/19/2016WedbushReiterated RatingOutperform$36.00View Rating Details
7/18/2016Robert W. BairdReiterated RatingOutperform$23.00View Rating Details
6/27/2016William BlairReiterated RatingMarket PerformView Rating Details
6/25/2016Jefferies GroupReiterated RatingUnderperform$7.00View Rating Details
6/9/2016Piper Jaffray Cos.UpgradeUnderweight -> NeutralView Rating Details
6/8/2016WBB SecuritiesReiterated RatingBuy$40.00View Rating Details
6/3/2016Royal Bank Of CanadaReiterated RatingHold$5.00View Rating Details
5/27/2016SunTrust Banks Inc.Reiterated RatingReduceView Rating Details
5/5/2016Ladenburg ThalmannDowngradeMarket Perform -> Underperform$13.00 -> $5.00View Rating Details
11/8/2015Roth CapitalReiterated RatingBuy$50.00View Rating Details
10/23/2015Bank of America Corp.Initiated CoverageBuy$49.00View Rating Details
9/1/2015SusquehannaBoost Price TargetNeutral$33.00 -> $36.00View Rating Details
5/23/2015Deutsche Bank AGReiterated RatingHold$24.00View Rating Details
5/20/2015Canaccord GenuityUpgradeHold -> Buy$16.00 -> $30.00View Rating Details
1/27/2015Northland SecuritiesUpgradeMarket Perform -> Outperform$3.00View Rating Details
10/27/2014Stifel NicolausDowngradeBuy -> HoldView Rating Details
10/7/2014Credit Suisse Group AGReiterated RatingOutperformView Rating Details
(Data available from 8/28/2014 forward)


Earnings History for Sarepta Therapeutics (NASDAQ:SRPT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/19/2016Q2($1.19)($1.35)ViewN/AView Earnings Details
5/5/2016Q1($1.30)($1.15)$0.18 millionViewN/AView Earnings Details
2/24/2016Q4($1.18)($1.30)$1.25 millionViewN/AView Earnings Details
11/5/2015Q315($1.19)($1.25)ViewListenView Earnings Details
8/6/2015Q215($1.21)($1.01)$0.31 million$0.01 millionViewListenView Earnings Details
5/7/2015Q115($1.00)($1.49)$0.78 millionViewListenView Earnings Details
2/26/2015Q414($0.82)($0.94)$1.56 million$0.30 millionViewListenView Earnings Details
11/6/2014Q314($0.96)($0.70)$3.07 million$1.10 millionViewListenView Earnings Details
8/7/2014Q214($0.76)($0.85)$4.30 million$2.58 millionViewListenView Earnings Details
5/8/2014Q114($0.80)($0.75)$3.45 million$6.09 millionViewListenView Earnings Details
2/27/2014Q413($0.69)($0.77)$4.53 million$2.60 millionViewListenView Earnings Details
11/12/2013Q313($0.65)($0.63)$4.57 million$4.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.67)($0.46)$5.08 million$3.00 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.62)($0.41)$5.85 million$4.50 millionViewListenView Earnings Details
3/7/2013Q4 2012($0.26)($2.36)$6.71 million$7.30 millionViewListenView Earnings Details
11/7/2012($0.27)($2.17)$10.06 million$7.57 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Sarepta Therapeutics (NASDAQ:SRPT)
Current Year EPS Consensus Estimate: $-5.16 EPS
Next Year EPS Consensus Estimate: $-3.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($1.40)($1.17)($1.29)
Q2 20165($1.32)($0.62)($1.08)
Q3 20166($1.34)($0.59)($0.97)
Q4 20166($1.31)($0.47)($0.86)
Q1 20171($0.68)($0.68)($0.68)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.49)($0.49)($0.49)
Q4 20171($0.39)($0.39)($0.39)
(Data provided by Zacks Investment Research)


Dividend History for Sarepta Therapeutics (NASDAQ:SRPT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Sarepta Therapeutics (NASDAQ:SRPT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/16/2016M Kathleen BehrensDirectorBuy10,000$14.54$145,400.00View SEC Filing  
3/14/2016M Kathleen BehrensDirectorBuy65,000$16.54$1,075,100.00View SEC Filing  
11/14/2013Anthony ChaseDirectorBuy10,000$13.95$139,500.00View SEC Filing  
9/16/2013M Kathleen BehrensDirectorBuy6,500$37.04$240,760.00View SEC Filing  
9/3/2013John HodgmanDirectorSell5,556$34.97$194,293.32View SEC Filing  
8/22/2013Anthony ChaseDirectorBuy3,500$32.68$114,380.00View SEC Filing  
8/20/2013Sandesh MahatmeCFOBuy5,000$31.10$155,500.00View SEC Filing  
6/14/2013Anthony R ChaseDirectorBuy10,000$38.50$385,000.00View SEC Filing  
9/7/2012M Kathleen BehrensDirectorBuy17,500$14.73$257,775.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Sarepta Therapeutics (NASDAQ:SRPT)
DateHeadline logoMost Active Options: Apple Inc. and Sarepta Therapeutics Inc (NASDAQ:SRPT) - August 26 at 7:12 PM
News IconActive biotech company shares in the news: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Galena Biopharma, Inc ... - The Voice Registrar (NASDAQ:SRPT) - August 25 at 7:49 PM
News IconIntraday Active Biotech Stocks News: Gilead Sciences Inc. (NASDAQ:GILD), Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - The Voice Registrar (NASDAQ:SRPT) - August 24 at 7:15 PM
News IconActive biotech company shares in the news: Sarepta Therapeutics ... - The Voice Registrar (NASDAQ:SRPT) - August 23 at 7:42 PM logoNotable Monday Option Activity: SRPT, ALNY, SWFT (NASDAQ:SRPT) - August 22 at 7:27 PM
News IconIntraday Active Biotech Stocks News: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), ImmunoCellular Therapeutics, Ltd ... - The Voice Registrar (NASDAQ:SRPT) - August 22 at 11:57 AM logoSAREPTA THERAPEUTICS, INC. Financials (NASDAQ:SRPT) - August 18 at 7:48 PM
News Icon2 Biotech Stocks News And Price Trends: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Cyclacel Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:SRPT) - August 17 at 10:35 AM logoCowen Weighs in on Sarepta Therapeutics Inc (SRPT) Following 2Q ... - Smarter Analyst (NASDAQ:SRPT) - August 14 at 11:30 AM logoCowen Weighs in on Sarepta Therapeutics Inc (SRPT) Following 2Q:16 Report (NASDAQ:SRPT) - August 12 at 7:41 PM logoSarepta: The Competition Is At The Gate - Seeking Alpha (NASDAQ:SRPT) - August 11 at 8:05 PM logoFDA Delay Sparks Bearish Backlash On Sarepta Therapeutics Inc ... - Schaeffers Research (blog) (NASDAQ:SRPT) - August 11 at 8:05 PM logoDownside Risk In Sarepta Shares Greater Than Upside Potential, Janney Says (NASDAQ:SRPT) - August 10 at 8:04 PM logoSarepta Therapeutics: Patience Will Not Be Rewarded (NASDAQ:SRPT) - August 10 at 8:04 PM
News IconHealthcare Sector Movers: Sarepta Therapeutics, Inc. (NASDAQ ... - TWN (NASDAQ:SRPT) - August 10 at 10:43 AM logoSarepta Therapeutics Inc (SRPT) Option Bears Eye a Huge Drop Ahead - Schaeffers Research (blog) (NASDAQ:SRPT) - August 10 at 10:43 AM logoSarepta Therapeutics: Here We Go Again (NASDAQ:SRPT) - August 10 at 10:43 AM logoSarepta Therapeutics (SRPT) Stock Falls, Janney: 'Stay on the Sidelines' (NASDAQ:SRPT) - August 10 at 10:43 AM logoSarepta Therapeutics Inc (SRPT) Option Bears Eye a Huge Drop Ahead (NASDAQ:SRPT) - August 9 at 7:52 PM logoSAREPTA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:SRPT) - August 9 at 7:52 PM logo[$$] Heart of Bureaucratic Darkness (NASDAQ:SRPT) - August 9 at 7:52 PM logoIs Sarepta Therapeutics Still a Buy After Surging Higher in July? (NASDAQ:SRPT) - August 9 at 9:16 AM logoSarepta Therapeutics (SRPT) Shares are Up 4.27% – Trade Calls - Trade Calls (NASDAQ:SRPT) - August 8 at 11:54 AM logoWhy Sarepta Therapeutics is Soaring (NASDAQ:SRPT) - August 4 at 10:47 AM logoSarepta (SRPT) Stock Advances on Phase III Trial Recruitment (NASDAQ:SRPT) - August 4 at 10:47 AM logoAnalyst Update: Sarepta Therapeutics Inc, Zynga Inc, and Oclaro, Inc. - Schaeffers Research (blog) (NASDAQ:SRPT) - August 3 at 7:57 PM logoSarepta Therapeutics Inc (SRPT) Stock Soared Today: Here's Why - Bidness ETC (NASDAQ:SRPT) - August 3 at 7:57 PM
News IconBiotechnology Stocks Grabbing Investor's Attention: Sarepta Therapeutics Inc (NASDAQ:SRPT), BioMarin ... - Post Registrar (NASDAQ:SRPT) - August 2 at 12:12 PM logoAnalysts Spotlight: Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS ... - Street Updates (NASDAQ:SRPT) - August 1 at 11:57 AM
News IconSarepta Therapeutics Inc (NASDAQ:SRPT): This Chart Shows ... - Profit Confidential (NASDAQ:SRPT) - July 29 at 10:40 AM logoHow Focusing On Obscure Diseases Made BioMarin A $15 Billion Company (NASDAQ:SRPT) - July 28 at 8:30 AM logoLatest Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Target Price ... - Review Fortune (NASDAQ:SRPT) - July 27 at 7:58 PM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) Insider Activities Are in the Air - Review Fortune (NASDAQ:SRPT) - July 26 at 10:59 AM logoRevenue Update on Sarepta Therapeutics Inc(NASDAQ:SRPT ... - Trade Calls (NASDAQ:SRPT) - July 26 at 10:59 AM logoSarepta Therapeutics, Inc. (NASDAQ:SRPT) soared 5.47%: MannKind Corp. (NASDAQ:MNKD), MetLife, Inc. (NYSE ... - KC Register (NASDAQ:SRPT) - July 25 at 11:57 AM logoSarepta Therapeutics Inc. (SRPT) Jumps 5.47% on July 22 - (NASDAQ:SRPT) - July 23 at 11:21 AM logoAnalyst Update: athenahealth, Inc, Adeptus Health Inc, and Sarepta Therapeutics Inc (NASDAQ:SRPT) - July 22 at 7:23 PM logoAnalyst Rating Trends to Observe: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) , Baxter International Inc. (NYSE:BAX) - Street Updates (NASDAQ:SRPT) - July 22 at 10:28 AM logoBroker Outlook For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Fiscal Standard (NASDAQ:SRPT) - July 22 at 10:28 AM
News IconPrice Target Spotlight: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - News Oracle (NASDAQ:SRPT) - July 22 at 10:28 AM logoSarepta Therapeutics Inc. (SRPT) Jumps 6.24% on July 20 - (NASDAQ:SRPT) - July 22 at 10:28 AM logoJMP Securities Chimes In on Sarepta Therapeutics Inc (SRPT) Following 2Q Update; Awaits FDA Decision on Eteplirsen - Smarter Analyst (NASDAQ:SRPT) - July 22 at 10:28 AM logoSRPT Makes Bullish Cross Above Critical Moving Average (NASDAQ:SRPT) - July 21 at 7:53 PM logoWhy Investors Flocked to Sarepta Therapeutics This Week (NASDAQ:SRPT) - July 21 at 11:02 AM logoWedbush Upgrades Rating On Sarepta Therapeutics, Inc. (SRPT) - Finance Daily (NASDAQ:SRPT) - July 20 at 8:32 PM logoAnalyst's Focused Stocks Endo International (ENDP) , Sarepta Therapeutics, Inc. (SRPT) - Street Updates (NASDAQ:SRPT) - July 20 at 8:32 PM logoCowen Weighs In on Sarepta Therapeutics Inc (SRPT) in Light of More Regulatory Setbacks in DMD Field - Smarter Analyst (NASDAQ:SRPT) - July 20 at 8:32 PM logoSarepta Therapeutics : reports 2Q loss (NASDAQ:SRPT) - July 20 at 10:30 AM logoSarepta Therapeutics Announces Second Quarter 2016 Financial Results and Recent Corporate Developments (NASDAQ:SRPT) - July 20 at 10:30 AM logoSarepta Therapeutics (SRPT) Stock Falls on Q2 Earnings Loss (NASDAQ:SRPT) - July 20 at 9:47 AM


Sarepta Therapeutics (NASDAQ:SRPT) Chart for Sunday, August, 28, 2016

Last Updated on 8/28/2016 by Staff